Physician profile
David Carlson
NPI 1700961406
$7,838.44
in general payments reported to CMS, 2019-2025
45 companies · $875 in 2025
The $875 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,344 · 2020: $843 · 2021: $809 · 2022: $917 · 2023: $1,141 · 2024: $910 · 2025: $875.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,831 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,831.37 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,260.19 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $1,197.90 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $728.70 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $505.31 | 2019-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $488.14 | 2019-2023 | Dificid |
| Pfizer INC. | $435.99 | 2019-2025 | |
| Allergan, INC. | $283.40 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $263.38 | 2019-2024 | Xarelto |
| Abbott Laboratories | $209.71 | 2023-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $199.92 | 2019-2022 | |
| Amgen INC. | $199.83 | 2019-2025 | Otezla, Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $184.50 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.98 | 2019-2024 | Jardiance |
| Idorsia Pharmaceuticals US INC | $171.97 | 2022-2024 | Quviviq |
| Abbvie INC. | $139.27 | 2022-2025 | Vraylar, Ubrelvy |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Carlson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.